New clinical approaches are imperative beyond the widely adopted National Comprehensive Cancer Network (NCCN) guidelines, utilized by prominent cancer institutions. Cancer is the leading cause of death among individua...New clinical approaches are imperative beyond the widely adopted National Comprehensive Cancer Network (NCCN) guidelines, utilized by prominent cancer institutions. Cancer is the leading cause of death among individuals younger than 85 years within the United States. Despite significant technological advances, including the expenditure of hundreds of billions, treatment outcomes and overall survival have not notably improved for most types of advanced cancer over the last several decades. Over the past 24 years, Envita Medical Centers has pioneered a unique form of personalized treatment approach for late-stage and refractory cancer patients, introducing groundbreaking innovations in the field. Our integrated algorithm utilizes advanced genomics, transcriptomics, and highly tailored immunotherapy, resulting in remarkable outcome improvements. This study presents Envita’s innovative personalized treatment algorithms and examines the response outcomes of 199 late-stage cancer patients treated at Envita Medical Centers over a two-year period. Compared to standard of care and palliative chemotherapy, Envita’s treatment demonstrated a remarkable 35-fold improvement in overall response rates (Figure 1). Moreover, 88% of the patients, the majority presenting with Stage 3 or 4 cancer, experienced a 43-fold improvement in quality of life with minimal side effects, as compared to standard of care chemotherapy and palliative care. This revolutionary success is attributed to Envita’s personalized therapeutic algorithms, which incorporate customized immunotherapy. Envita’s precision care approach has also achieved a 100% better response rate compared to over 65 global chemotherapy clinical trials with more than 2700 patients. The results from this study suggest that a wider utilization of Envita’s personalized approach can significantly benefit patients with late-stage and refractory cancer.展开更多
There is a great deal of literature on the effects of sand burial upon the survival and growth of desert plants, but the physiological adaption mechanisms of desert plants to sand burial have as yet rarely been studie...There is a great deal of literature on the effects of sand burial upon the survival and growth of desert plants, but the physiological adaption mechanisms of desert plants to sand burial have as yet rarely been studied. Artemisia halodendron is widely distributed in the semi-arid deserts of China and is a dominant species in semi-moving dune vegetation. The growth and physiological properties ofA. halodendron seedlings under different sand burial depths were studied in 2010 and 2011 in the Horqin Sand Land, Inner Mongolia, to better understand the ability and physiological mechanism by which desert plants withstand sand burial. The results showed that A. halodendron as a prammophyte species had a stronger ability to withstand sand burial compared to non-prammophytes, with some plants still surviving even if buried to a depth reaching 225% of seedling height. Although seedling growth was inhibited significantly once the depth of sand burial reached 50% of the seedling height, seedling survival did not decrease significantly until the burial depth exceeded 100% of the seedling height. Sand burial did not result in significant water stress or MDA （Malondialdehyde） accumulation in the seedlings, but membrane permeability increased significantly when the burial depth exceeded 100% of the seedling height. After being subjected to sand burial stress, POD （Peroxidase） activity and proline content increased significantly, but SOD （Superoxide Dismutase） and POD activities and soluble sugar content did not. The primary mechanism resulting in in- creased mortality and growth inhibition were that cell membranes were damaged and photosynthetic area decreased when subjected to the severe stress of sand burial, while proline and POD played key roles in osmotic adjustment and protecting cell membranes from damage, respectively.展开更多
Background and objective Non-small cell lung cancer (NSCLC) stages over IIIb still remain as an intractable disease.Survival rate of NSCLC stages over IIIb could be increased through chemotherapy and radiation,but res...Background and objective Non-small cell lung cancer (NSCLC) stages over IIIb still remain as an intractable disease.Survival rate of NSCLC stages over IIIb could be increased through chemotherapy and radiation,but results are not satisfactory.Oriental medicine herbal formula,HangAm-Dan (HAD) has been developed for anti-tumor purpose and several previous studies have already reported its effects.The aim of this study is to assess HAD's efficacy on prolonging the survival rate of NSCLC stages over IIIb.Methods We have administered 3 000 mg of HAD daily to patients.The study included 74 first visit patients of East-West Cancer Center (EWCC) from November 2007 to April 2008,diagnosed with inoperable NSCLC stages over IIIb.Among them,30 patients were in HAD group and 44 patients were in combined group with conventional therapy and HAD.We have observed and analyzed their overall survival.Results Of total 74 patients,overall 1 year,2 year survival rates and the median survival time were 62.1%,34.9% and 17.0 months (95%CI: 12.9-21.1).NSCLC stage IIIb patients showed higher survival rates than NSCLC stage IV patients (P=0.408).The 1 year,2 year survival rates and the median survival time of the combined group were 70.5%,37.9% and 20.0 months (95%CI: 16.4-24.6).In HAD group,the 1 year,2 year survival rates and the median survival time were 50.0%,25.7% and 12.0 months (95%CI: 6.6-17.4).The combined therapy group showed higher survival rates than the HAD group (P=0.034).Each groups treated with HAD for more than 4 weeks showed higher survival rates than those treated for less than 4 weeks,but there was no significant difference (P=0.278).In hazard ratio,the combined therapy group showed lower mortality rate than the HAD group with statistical significance (P=0.040).Conclusion HAD could prolong the survival rate of inoperable NSCLC stages over IIIb.HAD is more effective when combined with conventional therapy.In the future,more controlled clinical trials with larger sample in multi-centers are needed to reevaluate the efficacy and safety of HAD.Keywords Lung neoplasms; HangAm-Dan; Oriental medicine; Overall survival rate; Cancer; Herb Abstract Background and objective Non-small cell lung cancer (NSCLC) stages over IIIb still remain as an intractable disease.Survival rate of NSCLC stages over IIIb could be increased through chemotherapy and radiation,but results are not satisfactory.Oriental medicine herbal formula,HangAm-Dan (HAD) has been developed for anti-tumor purpose and several previous studies have already reported its effects.The aim of this study is to assess HAD's efficacy on prolonging the survival rate of NSCLC stages over IIIb.Methods We have administered 3 000 mg of HAD daily to patients.The study included 74 first visit patients of East-West Cancer Center (EWCC) from November 2007 to April 2008,diagnosed with inoperable NSCLC stages over IIIb.Among them,30 patients were in HAD group and 44 patients were in combined group with conventional therapy and HAD.We have observed and analyzed their overall survival.Results Of total 74 patients,overall 1 year,2 year survival rates and the median survival time were 62.1%,34.9% and 17.0 months (95%CI: 12.9-21.1).NSCLC stage IIIb patients showed higher survival rates than NSCLC stage IV patients (P=0.408).The 1 year,2 year survival rates and the median survival time of the combined group were 70.5%,37.9% and 20.0 months (95%CI: 16.4-24.6).In HAD group,the 1 year,2 year survival rates and the median survival time were 50.0%,25.7% and 12.0 months (95%CI: 6.6-17.4).The combined therapy group showed higher survival rates than the HAD group (P=0.034).Each groups treated with HAD for more than 4 weeks showed higher survival rates than those treated for less than 4 weeks,but there was no significant difference (P=0.278).In hazard ratio,the combined therapy group showed lower mortality rate than the HAD group with statistical significance (P=0.040).Conclusion HAD could prolong the survival rate of inoperable NSCLC stages over IIIb.HAD is more effective when combined with conventional therapy.In the future,more controlled clinical trials with larger sample in multi-centers are needed to reevaluate the efficacy and safety of HAD.展开更多
BACKGROUND The recurrence rate of liver cancer after surgery is high.Radiofrequency ablation(RFA)combined with transcatheter arterial chemoembolization(TACE)is an effective treatment for liver cancer;however,its effic...BACKGROUND The recurrence rate of liver cancer after surgery is high.Radiofrequency ablation(RFA)combined with transcatheter arterial chemoembolization(TACE)is an effective treatment for liver cancer;however,its efficacy in recurrent liver cancer remains unclear.AIM To investigate the clinical effect of TACE combined with RFA in the treatment of recurrent liver cancer.METHODS Ninety patients with recurrent liver cancer were divided into 2 groups according to treatment plan:Control(RFA alone);and experimental[TACE combined with RFA(TACE+RFA)].The incidence of increased alanine aminotransferase levels,complications,and other indices were compared between the two groups before and after the procedures.RESULTS One month after the procedures,the short-term efficacy rate and Karnofsky Performance Status scores of the experimental group were significantly higher than those of the control group(P<0.05).Alpha-fetoprotein(AFP)and total bilirubin levels were lower than those in the control group(P<0.05);The overall response rate was 82.22%and 66.67%in the experimental and control groups,respectively;The disease control rate was 93.33%and 82.22%in the experimental and control groups,respectively,the differences are statistically significant(P<0.05).And there were no statistical differences in complications between the two groups(P>0.05).CONCLUSION TACE+RFA was effective for the treatment of recurrent liver cancer and significantly reduced AFP levels and improved various indices of liver function.展开更多
BACKGROUND The combination of programmed cell death protein-1(PD-1)inhibitor and che-motherapy is approved as a standard first-or second-line treatment in patients with advanced oesophageal or gastric cancer.However,i...BACKGROUND The combination of programmed cell death protein-1(PD-1)inhibitor and che-motherapy is approved as a standard first-or second-line treatment in patients with advanced oesophageal or gastric cancer.However,it is unclear whether this combination is superior to chemotherapy alone.AIM To assess the comparative effectiveness and tolerability of combining PD-1 inhibitors with chemotherapy vs chemotherapy alone in patients with advanced gastric cancer,gastroesophageal junction(GEJ)cancer,or oesophageal carcinoma.METHODS We searched the PubMed and Embase databases for studies that compared the efficacy and tolerance of PD-1 inhibitors in combination with chemotherapy vs chemotherapy alone in patients with advanced oesophageal or gastric cancer.We employed either random or fixed models to analyze the outcomes of each clinical trial,en-compassing data on overall survival(OS),progression-free survival(PFS),objective response rate,and adverse events(AEs).RESULTS Nine phase 3 clinical trials(7016 advanced oesophageal and gastric cancer patients)met the inclusion criteria.Our meta-analysis demonstrated that the pooled PD-1 inhibitor+chemotherapy group had a significantly longer OS than the chemotherapy-alone group[hazard ratio(HR)=0.76,95%confidence interval(CI):0.71-0.81];the pooled PFS result was consistent with that of OS(HR=0.67,95%CI:0.61-0.74).The count of patients achieving an objective response in the PD-1 inhibitor+chemotherapy group surpassed that of the chemotherapy-alone group[odds ratio(OR)=1.86,95%CI:1.59-2.18].AE incidence was also higher in the combination-therapy group than in the chemotherapy-alone group,regardless of whether≥grade 3 only(OR=1.30,95%CI:1.07-1.57)or all AE grades(OR=1.88,95%CI:1.39-2.54)were examined.We performed a subgroup analysis based on the programmed death-ligand 1(PD-L1)combined positive score(CPS)and noted extended OS and PFS durations within the CPS≥1,CPS≥5,and CPS≥10 subgroups of the PD-1 inhibitor+chemotherapy group.CONCLUSION In contrast to chemotherapy alone,the combination of PD-1 inhibitor and chemotherapy appears to present a more favorable option for initial or subsequent treatment in patients with gastric cancer,GEJ tumor,or oesophageal cancer.This holds true particularly for individuals with PD-L1 CPS scores of≥5 and≥10.展开更多
目的:基于监测、流行病学和最终结果(surveillance,epidemiology,and end results,SEER)数据库,分析影响胰腺癌预后的独立因素并构建预测模型。方法:本研究从SEER数据库获取2010-2015年美国7801例胰腺癌病人的临床资料,以7∶3的比例随...目的:基于监测、流行病学和最终结果(surveillance,epidemiology,and end results,SEER)数据库,分析影响胰腺癌预后的独立因素并构建预测模型。方法:本研究从SEER数据库获取2010-2015年美国7801例胰腺癌病人的临床资料,以7∶3的比例随机分为建模组、验证组。对建模组临床变量进行多因素COX回归分析获得影响生存的独立因素,构建列线图。通过受试者操作特性(receiver operating characteristic,ROC)曲线和校准曲线验证模型的准确性。结果:年龄、原发部位、病理分级、T分期、N分期、M分期、手术方式、放疗、化疗与胰腺癌的预后相关,总生存的3年、5年ROC曲线下面积(area under cure,AUC)分别为0.90、0.91,癌症特异性生存分别为0.91、0.91。校准曲线显示观察值与预测值之间具有良好的一致性。经筛选得到的临床变量确实对胰腺癌预后有影响。结论:所构建的模型具有较好的预测准确性,有助于胰腺癌病人的临床决策和个性化治疗。展开更多
文摘New clinical approaches are imperative beyond the widely adopted National Comprehensive Cancer Network (NCCN) guidelines, utilized by prominent cancer institutions. Cancer is the leading cause of death among individuals younger than 85 years within the United States. Despite significant technological advances, including the expenditure of hundreds of billions, treatment outcomes and overall survival have not notably improved for most types of advanced cancer over the last several decades. Over the past 24 years, Envita Medical Centers has pioneered a unique form of personalized treatment approach for late-stage and refractory cancer patients, introducing groundbreaking innovations in the field. Our integrated algorithm utilizes advanced genomics, transcriptomics, and highly tailored immunotherapy, resulting in remarkable outcome improvements. This study presents Envita’s innovative personalized treatment algorithms and examines the response outcomes of 199 late-stage cancer patients treated at Envita Medical Centers over a two-year period. Compared to standard of care and palliative chemotherapy, Envita’s treatment demonstrated a remarkable 35-fold improvement in overall response rates (Figure 1). Moreover, 88% of the patients, the majority presenting with Stage 3 or 4 cancer, experienced a 43-fold improvement in quality of life with minimal side effects, as compared to standard of care chemotherapy and palliative care. This revolutionary success is attributed to Envita’s personalized therapeutic algorithms, which incorporate customized immunotherapy. Envita’s precision care approach has also achieved a 100% better response rate compared to over 65 global chemotherapy clinical trials with more than 2700 patients. The results from this study suggest that a wider utilization of Envita’s personalized approach can significantly benefit patients with late-stage and refractory cancer.
基金funded by the Chinese National Fund Projects (Nos.31270752 and 30972422)by a Chinese National Support Project of Science and Technology (No.2011BAC07B02-06)
文摘There is a great deal of literature on the effects of sand burial upon the survival and growth of desert plants, but the physiological adaption mechanisms of desert plants to sand burial have as yet rarely been studied. Artemisia halodendron is widely distributed in the semi-arid deserts of China and is a dominant species in semi-moving dune vegetation. The growth and physiological properties ofA. halodendron seedlings under different sand burial depths were studied in 2010 and 2011 in the Horqin Sand Land, Inner Mongolia, to better understand the ability and physiological mechanism by which desert plants withstand sand burial. The results showed that A. halodendron as a prammophyte species had a stronger ability to withstand sand burial compared to non-prammophytes, with some plants still surviving even if buried to a depth reaching 225% of seedling height. Although seedling growth was inhibited significantly once the depth of sand burial reached 50% of the seedling height, seedling survival did not decrease significantly until the burial depth exceeded 100% of the seedling height. Sand burial did not result in significant water stress or MDA （Malondialdehyde） accumulation in the seedlings, but membrane permeability increased significantly when the burial depth exceeded 100% of the seedling height. After being subjected to sand burial stress, POD （Peroxidase） activity and proline content increased significantly, but SOD （Superoxide Dismutase） and POD activities and soluble sugar content did not. The primary mechanism resulting in in- creased mortality and growth inhibition were that cell membranes were damaged and photosynthetic area decreased when subjected to the severe stress of sand burial, while proline and POD played key roles in osmotic adjustment and protecting cell membranes from damage, respectively.
文摘Background and objective Non-small cell lung cancer (NSCLC) stages over IIIb still remain as an intractable disease.Survival rate of NSCLC stages over IIIb could be increased through chemotherapy and radiation,but results are not satisfactory.Oriental medicine herbal formula,HangAm-Dan (HAD) has been developed for anti-tumor purpose and several previous studies have already reported its effects.The aim of this study is to assess HAD's efficacy on prolonging the survival rate of NSCLC stages over IIIb.Methods We have administered 3 000 mg of HAD daily to patients.The study included 74 first visit patients of East-West Cancer Center (EWCC) from November 2007 to April 2008,diagnosed with inoperable NSCLC stages over IIIb.Among them,30 patients were in HAD group and 44 patients were in combined group with conventional therapy and HAD.We have observed and analyzed their overall survival.Results Of total 74 patients,overall 1 year,2 year survival rates and the median survival time were 62.1%,34.9% and 17.0 months (95%CI: 12.9-21.1).NSCLC stage IIIb patients showed higher survival rates than NSCLC stage IV patients (P=0.408).The 1 year,2 year survival rates and the median survival time of the combined group were 70.5%,37.9% and 20.0 months (95%CI: 16.4-24.6).In HAD group,the 1 year,2 year survival rates and the median survival time were 50.0%,25.7% and 12.0 months (95%CI: 6.6-17.4).The combined therapy group showed higher survival rates than the HAD group (P=0.034).Each groups treated with HAD for more than 4 weeks showed higher survival rates than those treated for less than 4 weeks,but there was no significant difference (P=0.278).In hazard ratio,the combined therapy group showed lower mortality rate than the HAD group with statistical significance (P=0.040).Conclusion HAD could prolong the survival rate of inoperable NSCLC stages over IIIb.HAD is more effective when combined with conventional therapy.In the future,more controlled clinical trials with larger sample in multi-centers are needed to reevaluate the efficacy and safety of HAD.Keywords Lung neoplasms; HangAm-Dan; Oriental medicine; Overall survival rate; Cancer; Herb Abstract Background and objective Non-small cell lung cancer (NSCLC) stages over IIIb still remain as an intractable disease.Survival rate of NSCLC stages over IIIb could be increased through chemotherapy and radiation,but results are not satisfactory.Oriental medicine herbal formula,HangAm-Dan (HAD) has been developed for anti-tumor purpose and several previous studies have already reported its effects.The aim of this study is to assess HAD's efficacy on prolonging the survival rate of NSCLC stages over IIIb.Methods We have administered 3 000 mg of HAD daily to patients.The study included 74 first visit patients of East-West Cancer Center (EWCC) from November 2007 to April 2008,diagnosed with inoperable NSCLC stages over IIIb.Among them,30 patients were in HAD group and 44 patients were in combined group with conventional therapy and HAD.We have observed and analyzed their overall survival.Results Of total 74 patients,overall 1 year,2 year survival rates and the median survival time were 62.1%,34.9% and 17.0 months (95%CI: 12.9-21.1).NSCLC stage IIIb patients showed higher survival rates than NSCLC stage IV patients (P=0.408).The 1 year,2 year survival rates and the median survival time of the combined group were 70.5%,37.9% and 20.0 months (95%CI: 16.4-24.6).In HAD group,the 1 year,2 year survival rates and the median survival time were 50.0%,25.7% and 12.0 months (95%CI: 6.6-17.4).The combined therapy group showed higher survival rates than the HAD group (P=0.034).Each groups treated with HAD for more than 4 weeks showed higher survival rates than those treated for less than 4 weeks,but there was no significant difference (P=0.278).In hazard ratio,the combined therapy group showed lower mortality rate than the HAD group with statistical significance (P=0.040).Conclusion HAD could prolong the survival rate of inoperable NSCLC stages over IIIb.HAD is more effective when combined with conventional therapy.In the future,more controlled clinical trials with larger sample in multi-centers are needed to reevaluate the efficacy and safety of HAD.
文摘BACKGROUND The recurrence rate of liver cancer after surgery is high.Radiofrequency ablation(RFA)combined with transcatheter arterial chemoembolization(TACE)is an effective treatment for liver cancer;however,its efficacy in recurrent liver cancer remains unclear.AIM To investigate the clinical effect of TACE combined with RFA in the treatment of recurrent liver cancer.METHODS Ninety patients with recurrent liver cancer were divided into 2 groups according to treatment plan:Control(RFA alone);and experimental[TACE combined with RFA(TACE+RFA)].The incidence of increased alanine aminotransferase levels,complications,and other indices were compared between the two groups before and after the procedures.RESULTS One month after the procedures,the short-term efficacy rate and Karnofsky Performance Status scores of the experimental group were significantly higher than those of the control group(P<0.05).Alpha-fetoprotein(AFP)and total bilirubin levels were lower than those in the control group(P<0.05);The overall response rate was 82.22%and 66.67%in the experimental and control groups,respectively;The disease control rate was 93.33%and 82.22%in the experimental and control groups,respectively,the differences are statistically significant(P<0.05).And there were no statistical differences in complications between the two groups(P>0.05).CONCLUSION TACE+RFA was effective for the treatment of recurrent liver cancer and significantly reduced AFP levels and improved various indices of liver function.
文摘BACKGROUND The combination of programmed cell death protein-1(PD-1)inhibitor and che-motherapy is approved as a standard first-or second-line treatment in patients with advanced oesophageal or gastric cancer.However,it is unclear whether this combination is superior to chemotherapy alone.AIM To assess the comparative effectiveness and tolerability of combining PD-1 inhibitors with chemotherapy vs chemotherapy alone in patients with advanced gastric cancer,gastroesophageal junction(GEJ)cancer,or oesophageal carcinoma.METHODS We searched the PubMed and Embase databases for studies that compared the efficacy and tolerance of PD-1 inhibitors in combination with chemotherapy vs chemotherapy alone in patients with advanced oesophageal or gastric cancer.We employed either random or fixed models to analyze the outcomes of each clinical trial,en-compassing data on overall survival(OS),progression-free survival(PFS),objective response rate,and adverse events(AEs).RESULTS Nine phase 3 clinical trials(7016 advanced oesophageal and gastric cancer patients)met the inclusion criteria.Our meta-analysis demonstrated that the pooled PD-1 inhibitor+chemotherapy group had a significantly longer OS than the chemotherapy-alone group[hazard ratio(HR)=0.76,95%confidence interval(CI):0.71-0.81];the pooled PFS result was consistent with that of OS(HR=0.67,95%CI:0.61-0.74).The count of patients achieving an objective response in the PD-1 inhibitor+chemotherapy group surpassed that of the chemotherapy-alone group[odds ratio(OR)=1.86,95%CI:1.59-2.18].AE incidence was also higher in the combination-therapy group than in the chemotherapy-alone group,regardless of whether≥grade 3 only(OR=1.30,95%CI:1.07-1.57)or all AE grades(OR=1.88,95%CI:1.39-2.54)were examined.We performed a subgroup analysis based on the programmed death-ligand 1(PD-L1)combined positive score(CPS)and noted extended OS and PFS durations within the CPS≥1,CPS≥5,and CPS≥10 subgroups of the PD-1 inhibitor+chemotherapy group.CONCLUSION In contrast to chemotherapy alone,the combination of PD-1 inhibitor and chemotherapy appears to present a more favorable option for initial or subsequent treatment in patients with gastric cancer,GEJ tumor,or oesophageal cancer.This holds true particularly for individuals with PD-L1 CPS scores of≥5 and≥10.
文摘目的:基于监测、流行病学和最终结果(surveillance,epidemiology,and end results,SEER)数据库,分析影响胰腺癌预后的独立因素并构建预测模型。方法:本研究从SEER数据库获取2010-2015年美国7801例胰腺癌病人的临床资料,以7∶3的比例随机分为建模组、验证组。对建模组临床变量进行多因素COX回归分析获得影响生存的独立因素,构建列线图。通过受试者操作特性(receiver operating characteristic,ROC)曲线和校准曲线验证模型的准确性。结果:年龄、原发部位、病理分级、T分期、N分期、M分期、手术方式、放疗、化疗与胰腺癌的预后相关,总生存的3年、5年ROC曲线下面积(area under cure,AUC)分别为0.90、0.91,癌症特异性生存分别为0.91、0.91。校准曲线显示观察值与预测值之间具有良好的一致性。经筛选得到的临床变量确实对胰腺癌预后有影响。结论:所构建的模型具有较好的预测准确性,有助于胰腺癌病人的临床决策和个性化治疗。
